Literature DB >> 28078014

MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.

Songyan Wu1, Xiangfeng He2, Miao Li3, Fangfang Shi3, Di Wu3, Meng Pan3, Mei Guo3, Rong Zhang3, Shouhua Luo4, Ning Gu4, Jun Dou3.   

Abstract

Hematological malignancy originated from B-cell line, multiple myeloma (MM), is a kind of plasma cells in bone marrow hyperplasia and cause of osteoclast-mediated skeletal destruction disease. MiR-34a plays an important epigenetic regulating role in malignant tumors and presents a therapeutic potential. In this study, we investigated the effects of overexpression of miR-34a in MM cancer stem cells (CSCs) on tumor growth and bone lesions. Here we showed that miR-34a overexpression inhibited cell proliferation, colony formation, and increased CSC apoptosis in vitro. The apparent epigenetic modulation induced by miR-34a overexpression was found no only in MM RPMI8226 cells but also in CSC xenograft MM. Both bioinformatics prediction and dual-luciferase reporter assay showed that transforming growth interaction factor 2 (TGIF2) was sufficient to confer miR-34a regulation. The results of qRT-PCR and Western blot assays demonstrated that the expression of TGIF2 was significant decreased in tumor tissues from NOD/SCID mice injected with miR-34a-MM CSCs. We conclude that miR-34a overexpression in MM CSCs significantly suppressed the tumorigenicity and lytic bone lesions in mouse model by inducing apoptosis and inhibiting TGIF2 expression.

Entities:  

Keywords:  Multiple myeloma; cancer stem cells; miR-34a; transforming growth interaction factor 2

Year:  2016        PMID: 28078014      PMCID: PMC5209494     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  30 in total

1.  MicroRNA-34a inhibits tumor invasion and metastasis in gastric cancer by targeting Tgif2.

Authors:  Yang Hu; Qingha Pu; Bin Cui; Jia Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells.

Authors:  J Wang; D Zhou; X He; Y Wang; W Hu; L Jiang; J Dou
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2011-10-15       Impact factor: 1.770

3.  Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse.

Authors:  Xiangfeng He; Jing Wang; Fengshu Zhao; Fangliu Yu; Dengyu Chen; Kai Cai; Cuiping Yang; Junsong Chen; Jun Dou
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

4.  Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells.

Authors:  Takeshi Chiyomaru; Shinichiro Fukuhara; Sharanjot Saini; Shahana Majid; Guoren Deng; Varahram Shahryari; Inik Chang; Yuichiro Tanaka; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya; Soichiro Yamamura
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

5.  Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.

Authors:  Anja Heinemann; Fang Zhao; Sonali Pechlivanis; Jürgen Eberle; Alexander Steinle; Sven Diederichs; Dirk Schadendorf; Annette Paschen
Journal:  Cancer Res       Date:  2011-11-18       Impact factor: 12.701

6.  Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma.

Authors:  Cuiping Yang; Fei Xiong; Jing Wang; Jun Dou; Junsong Chen; Dengyu Chen; Yu Zhang; Shouhua Luo; Ning Gu
Journal:  Nanomedicine (Lond)       Date:  2013-03-27       Impact factor: 5.307

7.  Epirubicin-mediated expression of miR-302b is involved in osteosarcoma apoptosis and cell cycle regulation.

Authors:  Yi Zhang; Hao Hu; Lu Song; Lin Cai; Renxiong Wei; Wei Jin
Journal:  Toxicol Lett       Date:  2013-07-08       Impact factor: 4.372

8.  The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Authors:  Can Liu; Kevin Kelnar; Bigang Liu; Xin Chen; Tammy Calhoun-Davis; Hangwen Li; Lubna Patrawala; Hong Yan; Collene Jeter; Sofia Honorio; Jason F Wiggins; Andreas G Bader; Randy Fagin; David Brown; Dean G Tang
Journal:  Nat Med       Date:  2011-01-16       Impact factor: 53.440

9.  miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.

Authors:  Jing Y Krzeszinski; Wei Wei; HoangDinh Huynh; Zixue Jin; Xunde Wang; Tsung-Cheng Chang; Xian-Jin Xie; Lin He; Lingegowda S Mangala; Gabriel Lopez-Berestein; Anil K Sood; Joshua T Mendell; Yihong Wan
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

10.  Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.

Authors:  Ajay Sharma; Nishant R Sinha; Saad Siddiqui; Rajiv R Mohan
Journal:  Mol Vis       Date:  2015-08-28       Impact factor: 2.367

View more
  12 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.

Authors:  Yun Liu; Jinjun Jiang; Chaoqi Liu; Wensi Zhao; Yao Ma; Zhiwei Zheng; Qing Zhou; Yun Zhao
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 3.  MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.

Authors:  Ammad Ahmad Farooqi; Sobia Tabassum; Aamir Ahmad
Journal:  Int J Mol Sci       Date:  2017-10-02       Impact factor: 5.923

4.  MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer.

Authors:  Ai-Hua Chen; Yu-E Qin; Wen-Fan Tang; Jing Tao; Hua-Mei Song; Manzhen Zuo
Journal:  Cancer Cell Int       Date:  2017-06-09       Impact factor: 5.722

5.  MALAT1 promotes proliferation, migration, and invasion of MG63 cells by upregulation of TGIF2 via negatively regulating miR-129.

Authors:  Kai Liu; Yingang Zhang; Liang Liu; Qiling Yuan
Journal:  Onco Targets Ther       Date:  2018-12-04       Impact factor: 4.147

6.  Down-Regulated microRNA-34a Expression as a Prognostic Marker for Poor Osteosarcoma in Mice: A Systematic Review and Meta-Analysis.

Authors:  Wenyi Wang; Shaopu Hu; Junli Chang; Hongfeng Ruan; Wenlan Zhi; Xiaobo Wang; Qi Shi; Yongjun Wang; Yanping Yang
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

Review 7.  Potential Therapeutic Roles of Exosomes in Multiple Myeloma: A Systematic Review.

Authors:  Mengzhen Li; Bing Xia; Yi Wang; M James You; Yizhuo Zhang
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

Review 8.  Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.

Authors:  Amro M Soliman; Teoh Seong Lin; Pasuk Mahakkanukrauh; Srijit Das
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

9.  Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation.

Authors:  Man Yang; Lingxiu Zhang; Xiufeng Wang; Yanjun Zhou; Sun Wu
Journal:  Arch Med Sci       Date:  2018-03-08       Impact factor: 3.318

10.  Nuclear PKM2 promotes the progression of oral squamous cell carcinoma by inducing EMT and post-translationally repressing TGIF2.

Authors:  Fumie Tanaka; Shohei Yoshimoto; Kazuhiko Okamura; Tetsuro Ikebe; Shuichi Hashimoto
Journal:  Oncotarget       Date:  2018-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.